Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults

Clostridium Difficile Associated Disease Clinical Trial

Official title:
A Phase 1, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of Clostridium Difficile Vaccine Administered In Healthy Japanese Adults Aged 65 To 85 Years.

Status Completed

Clinical Trial Summary

The first-in-Japanese study B5091010 has been designed to evaluate the safety, tolerability, and immunogenicity of 2 antigen dose levels of C difficile vaccine when administered as one of two 3-dose regimens to healthy Japanese adults aged 65 to 85 years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clostridium Difficile Associated Disease

Clinical Trial Details

NCT number	NCT02725437
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 1
Start date	February 2016
Completion date	February 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01706367` - Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years	Phase 1
Completed	`NCT03579459` - Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age	Phase 3
Active, not recruiting	`NCT02117570` - A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.	Phase 2
Completed	`NCT02561195` - A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years	Phase 2
Completed	`NCT03918629` - Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study	Phase 3